DOI: 10.21276/sasjm.2018.4.12.5

Pages: 222-224

Glucantime® is the standard treatment for cutaneous leishmaniasis in Morocco. The purpose of our study was to specify the adverse effects of systemic Glucantim, prescribed for cutaneous leishmaniasis. This is a retrospective study, conducted within the Department of Dermatology of the University Hospital Mohamed VI Marrakesh - Morocco over a period of 13 years, from January 2003 to June 2016. All hospitalized cases for cutaneous leishmaniasis were included and treated by Glucantime® at the dose of 20mg / kg / day for 10 to 15 days intramuscularly. The side effects of Glucantime®, a type of stibo-intolerance accident, occurred in 8 patients, 21% of Glucantime intramuscular treatments. The predominant skin reactions were inflammatory erythematous placards (37.5%), generalized pruriginous skin rash (12.5%) and arthro-myalgia (12.5%). The time of onset of these adverse effects varies from 1 to 14 days after the start of treatment. No cases of renal failure or cardiac disorders have been reported. In our series, we did not notice any serious side effects; however, the occurrence of these is possible and urges us to institute strict surveillance especially in elderly and fussy subjects.